Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:QDEL
CUSIP74838J10
Phone858-552-1100
Debt
Debt-to-Equity Ratio0.22
Current Ratio1.10
Quick Ratio0.71
Price-To-Earnings
Trailing P/E Ratio-957.29
Forward P/E Ratio25.83
P/E Growth1.09
Sales & Book Value
Annual Sales$277.74 million
Price / Sales9.12
Cash Flow$1.0315 per share
Price / Cash62.86
Book Value$6.68 per share
Price / Book9.71
Profitability
EPS (Most Recent Fiscal Year)($0.07)
Net Income$-8,160,000.00
Net Margins4.63%
Return on Equity19.39%
Return on Assets7.46%
Miscellaneous
Employees1,193
Outstanding Shares39,050,000
Market Cap$2.67 billion
Quidel (NASDAQ:QDEL) Frequently Asked Questions
What is Quidel's stock symbol?
Quidel trades on the NASDAQ under the ticker symbol "QDEL."
How were Quidel's earnings last quarter?
Quidel Co. (NASDAQ:QDEL) released its earnings results on Tuesday, August, 7th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.12. The business had revenue of $103.16 million for the quarter, compared to analyst estimates of $102.15 million. Quidel had a return on equity of 19.39% and a net margin of 4.63%. View Quidel's Earnings History.
When is Quidel's next earnings date?
What price target have analysts set for QDEL?
8 brokerages have issued twelve-month price targets for Quidel's stock. Their forecasts range from $47.00 to $80.00. On average, they expect Quidel's share price to reach $68.50 in the next year. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Price Targets for Quidel.
What is the consensus analysts' recommendation for Quidel?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 6 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quidel.
Who are some of Quidel's key competitors?
Some companies that are related to Quidel include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER).
Who are Quidel's key executives?
Quidel's management team includes the folowing people:
- Mr. Douglas C. Bryant, Pres, CEO & Director (Age 60)
- Mr. Randall J. Steward, Chief Financial Officer (Age 64)
- Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 50)
- Dr. Werner Kroll, Sr. VP of R&D (Age 61)
- Mr. Edward Keith Russell, Sr. VP of North America Operations (Age 50)
Has Quidel been receiving favorable news coverage?
News articles about QDEL stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quidel earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Quidel.
Who are Quidel's major shareholders?
Quidel's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.84%), Fred Alger Management Inc. (3.09%), OppenheimerFunds Inc. (2.31%), Dimensional Fund Advisors LP (2.33%), Macquarie Group Ltd. (2.13%) and Gabelli Funds LLC (1.65%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Jack W Schuler, John Tamerius, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel.
Which institutional investors are selling Quidel stock?
QDEL stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Macquarie Group Ltd., Aristotle Capital Boston LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Eagle Boston Investment Management Inc. and Eagle Asset Management Inc.. Company insiders that have sold Quidel company stock in the last year include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Kenneth F Buechler, Mary Lake Ph D Polan, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Insider Buying and Selling for Quidel.
Which institutional investors are buying Quidel stock?
QDEL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rothschild Asset Management Inc., Fuller & Thaler Asset Management Inc., Pier Capital LLC, Fred Alger Management Inc., Sei Investments Co., Massachusetts Financial Services Co. MA and Putnam Investments LLC. View Insider Buying and Selling for Quidel.
How do I buy shares of Quidel?
Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quidel's stock price today?
One share of QDEL stock can currently be purchased for approximately $64.83.
How big of a company is Quidel?
Quidel has a market capitalization of $2.67 billion and generates $277.74 million in revenue each year. The company earns $-8,160,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Quidel employs 1,193 workers across the globe.
How can I contact Quidel?
Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected]
MarketBeat Community Rating for Quidel (NASDAQ QDEL)
MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
